New findings pave the way for a novel, next generation genetically attenuated parasite (GAP) vaccine against the deadliest form of malaria in humans.
A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus that causes the disease, when tested in animals and human cell cultures.
A team of Norwegian and Estonian researchers have established a cell culture that allows them to test antibody-laden plasma, drugs and drug combinations in the laboratory. A screen of 136 safe-in-human antiviral drugs and identified six promising candidates. One combination of two drugs was so effective that researchers hope others can begin clinical trials on the drugs now.
A tuberculosis vaccine developed 100 years ago also makes vaccinated persons less susceptible to other infections. While this effect has been recognized for a long time, it is not known what causes it. Together with colleagues from Australia and Denmark, researchers from Radboud university medical center the universities of Nijmegen and Bonn have now presented a possible answer to this question.
A national study measuring parental attitudes toward vaccinations found 6.1% were hesitant about routine childhood immunizations while nearly 26% were hesitant about the influenza vaccine.
A significant site of damage during COVID-19 infection is the lungs. Understanding how the lungs' immune cells are responding to viral infections could help scientists develop a vaccine. Now, a team of researchers led by Salk Professor Susan Kaech has discovered that the cells responsible for long-term immunity in the lungs can be activated more easily than previously thought. The insight could aid in the development of universal vaccines for influenza and the novel coronavirus.
Researchers at CDDEP, Johns Hopkins University, and the University of Maryland School of Medicine assessed the impact of influenza vaccination coverage on state-level antibiotic prescribing rates in the United States between 2010 and 2017.
Researchers have identified a set of potential immunodominant epitopes from the SARS-CoV-2 proteome. These epitopes are capable of generating both antibody- and cell-mediated immune responses. The findings of this work may thus contribute to developing a peptide vaccine against SARS-CoV-2 infections which can stop the COVID-19 outbreak and future pandemics caused by coronaviruses.
Interactive web-based tool 'EPIC' hosts and analyses comprehensive immune cell data to understand the mechanisms of immunity and how they respond to disease. * EPIC offers new possibilities into the prediction of clinical responses for precision medicine and the development of vaccines and therapies
Society's response to COVID-19 is harming ethnic minorities and migrants, according to global health experts writing in the Journal of the Royal Society of Medicine. The risk of contracting COVID-19, the severity of the illness and the risk of poor health related to the policies and actions responding to the pandemic are all increased in minority groups, the authors write.